Surgeon Gareth Honeybone wants wider access to zanidatamab to treat one of the deadliest cancers.
Trending
- Optimal Sequencing of Bispecific Antibodies and CAR T Cells Remains Unclear
- Pelareorep Earns FDA Fast Track Designation in Second-Line Anal Cancer
- FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
- How Center for Cancer and Blood Disorders Is Changing the Future of CAR-T Cancer Therapy | Health Care
- Ascites-derived lipid barrier at the T cell synapse
- Why It’s So Hard to Just Rest and Why We Need to Do It
- Ivonescimab/Chemotherapy Maintains OS Benefit in EGFR-Mutant NSCLC
- Managing Patient Preferences and Expectations in Frontline EGFR-Mutant NSCLC

